{"type":"trials","record":{"id":41409,"source_id":"clinicaltrials-gov","external_id":"NCT07776522","title":"Phase II Study of Subretinal JWK001 for Neovascular Age-Related Macular Degeneration","brief_summary":"This is a Phase II, randomized, open-label, active-controlled study designed to evaluate the preliminary efficacy and safety of a single subretinal administration of JWK001 at different dose levels in patients with neovascular age-related macular degeneration.","overall_status":"Recruiting","phases":["PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"West China Hospital","enrollment":50,"countries":["China"],"start_date":"2026-08-31","completion_date":"2032-01-14","last_update_date":"2026-08-20","source_url":"https://clinicaltrials.gov/study/NCT07776522","editorial_summary":"A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years to 85 Years","comparator":"Aflibercept Active Comparator Group","organization":"West China Hospital","interventions":["JWK001","Aflibercept (2.0 mg)"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Change from baseline in best-corrected visual acuity (BCVA) — Week 34","Change from baseline in BCVA — Week 50 and Year 5","Change from baseline in central retinal thickness (CRT) — Week 34, Week 50 and Year 5","Change from baseline in the area of Macular Neovascularization (MNV) — Week 34 and Week 50","Change from baseline in leakage area — Week 34 and Week 50","Annualized mean number of rescue treatments — Week 34, Week 50 and Year 5","Change from baseline in the 25-item National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) score — Week 34 a…","Frequencies and severities of all safety events — Week 34 and Year 5"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · NONE","source_has_results":false},"controlled_terms":["Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD","JWK001","Aflibercept (2.0 mg)"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct07776522","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2026-08-31 to 2032-01-14","comparator":"Aflibercept Active Comparator Group","confidence":"structured-source","population":"ALL · 50 Years to 85 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.807Z","intervention":["JWK001","Aflibercept (2.0 mg)"],"participants":50,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Change from baseline in best-corrected visual acuity (BCVA) — Week 34","Change from baseline in BCVA — Week 50 and Year 5","Change from baseline in central retinal thickness (CRT) — Week 34, Week 50 and Year 5","Change from baseline in the area of Macular Neovascularization (MNV) — Week 34 and Week 50","Change from baseline in leakage area — Week 34 and Week 50","Annualized mean number of rescue treatments — Week 34, Week 50 and Year 5","Change from baseline in the 25-item National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) score — Week 34 a…","Frequencies and severities of all safety events — Week 34 and Year 5"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41409","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}